PEACCEL listed in The Digest of Global AI in Pharma Investment

4 August 2021

PEACCEL is listed in The Digest of Global AI in Pharma Investment.https://www.linkedin.com/posts/alina-timoshenkova-5b0a6364_top-countries-in-ai-for-drug-discovery-sector-activity-6828674970089078784-xobr/

PEACCEL mentioned as a AI start-up to watch by NVIDIA

6 April 2021

PEACCEL mentioned as a AI start-up to watch by NVIDIA.Three Trends for Healthcare AI Startups To Watch Renee Y. | 19 mars 2021
https://www.linkedin.com/pulse/three-trends-healthcare-ai-startups-watch-renee-yao

PEACCEL listed in the Global AI-based Drug Discovery Market Report 2021: Market report by Cision (NYSE: CISN).

6 April 2021

PEACCEL listed in the Global AI-based Drug Discovery Market Report 2021:  Market report by Cision (NYSE: CISN).

https://www.prnewswire.com/news-releases/global-ai-based-drug-discovery-market-report-2021-current-market-landscape-and-future-potential-of-the-players-engaged-in-offering-ai-based-services-platforms-and-tools—forecast-to-2030-301231782.html

PEACCEL awarded by Wealth & Finance

15 February 2021

PEACCEL has just received two Artificial Intelligence Awards from Wealth & Finance :

 – Best Drug Development AI Partner 2020

– Most Innovative Clinical Data Science Platform : innov’SAR

Digital Magazine Link

PEACCEL awarded by CIO Review

25 January 2021

PEACCEL has just been nominated as most promising biotech solutions providers in Europe 2021.

Click the links below for more details:

HTML Link
Digital Magazine Link

PRAXISforum Enzymes for Industrial Applications 2020, 4-5 February 2020, Frankfurt, Germany

3 February 2020

Meet PEACCEL at PRAXISforum Enzymes for Industrial Applications 2020.

Rudy PANDJAITAN (Chief Business Officer) will be representing PEACCEL at this event.